By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AcelRx Pharmaceuticals 

575 Chesapeake Drive

Redwood City  California  94063  U.S.A.
Phone: 650-216-3500 Fax: 650-216-6500




Company News
AcelRx (ACRX) Appoints Raffi Asadorian As Chief Financial Officer 7/19/2017 6:50:56 AM
AcelRx (ACRX) Reports First Quarter 2017 Financial Results And Provides Corporate Update 5/9/2017 10:42:32 AM
AcelRx (ACRX) To Hold First Quarter 2017 Financial Results Conference Call And Webcast On Monday, May 8th, 2017 4/26/2017 10:45:29 AM
AcelRx (ACRX) Reports Publication Of Manuscripts Analyzing IV, Transdermal And Sublingual Patient-Controlled Analgesia Systems 4/13/2017 10:28:28 AM
AcelRx (ACRX) Release: EMA Begins Evaluation Of Marketing Application For Sublingual Sufentanil 30 Mcg Tablet (Arx-04) For Moderate-To-Severe Acute Pain 3/28/2017 6:57:25 AM
AcelRx (ACRX) Reports Fourth Quarter and Year End 2016 Financial Results 3/3/2017 9:45:01 AM
AcelRx (ACRX)' New Drug Application For DSUVIA Accepted For Filing With PDUFA Date Of October 12, 2017 2/27/2017 6:36:31 AM
AcelRx (ACRX) To Hold Annual 2016 Financial Results Conference Call And Webcast On Thursday, March 2nd, 2017 2/24/2017 7:20:05 AM
AcelRx (ACRX) Appoints Vincent J. Angotti Chief Executive Officer 2/17/2017 9:06:30 AM
AcelRx (ACRX) Provides Guidance On 2017 Milestones For ARX-04, Now Known As DSUVIA In The United States, For The Treatment Of Moderate-To-Severe Acute Pain 1/9/2017 7:32:11 AM